^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/29/2022
Excerpt:
Soft Tissue Sarcoma...Preferred regimens...Pembrolizumab in combination with axitinib
